187 related articles for article (PubMed ID: 11968011)
1. Estrogen and Myc negatively regulate expression of the EphA2 tyrosine kinase.
Zelinski DP; Zantek ND; Walker-Daniels J; Peters MA; Taparowsky EJ; Kinch MS
J Cell Biochem; 2002; 85(4):714-20. PubMed ID: 11968011
[TBL] [Abstract][Full Text] [Related]
2. EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity.
Lu M; Miller KD; Gokmen-Polar Y; Jeng MH; Kinch MS
Cancer Res; 2003 Jun; 63(12):3425-9. PubMed ID: 12810680
[TBL] [Abstract][Full Text] [Related]
3. Ligand binding up-regulates EphA2 messenger RNA through the mitogen-activated protein/extracellular signal-regulated kinase pathway.
Pratt RL; Kinch MS
Mol Cancer Res; 2003 Dec; 1(14):1070-6. PubMed ID: 14707290
[TBL] [Abstract][Full Text] [Related]
4. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.
Pasqualini JR; Chetrite GS
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):221-36. PubMed ID: 15860265
[TBL] [Abstract][Full Text] [Related]
5. Estrogen and insulin/IGF-1 cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1.
Mawson A; Lai A; Carroll JS; Sergio CM; Mitchell CJ; Sarcevic B
Mol Cell Endocrinol; 2005 Jan; 229(1-2):161-73. PubMed ID: 15607540
[TBL] [Abstract][Full Text] [Related]
6. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior.
Carles-Kinch K; Kilpatrick KE; Stewart JC; Kinch MS
Cancer Res; 2002 May; 62(10):2840-7. PubMed ID: 12019162
[TBL] [Abstract][Full Text] [Related]
7. Effects of c-myc overexpression on the growth characteristics of MCF-7 human breast cancer cells.
Liu E; Santos G; Lee WM; Osborne CK; Benz CC
Oncogene; 1989 Aug; 4(8):979-84. PubMed ID: 2668848
[TBL] [Abstract][Full Text] [Related]
8. Different expression patterns of Bcl-2 family genes in breast cancer by estrogen receptor status with special reference to pro-apoptotic Bak gene.
Eguchi H; Suga K; Saji H; Toi M; Nakachi K; Hayashi SI
Cell Death Differ; 2000 May; 7(5):439-46. PubMed ID: 10800077
[TBL] [Abstract][Full Text] [Related]
9. Membrane-bound melatonin receptor MT1 down-regulates estrogen responsive genes in breast cancer cells.
Girgert R; Hanf V; Emons G; Gründker C
J Pineal Res; 2009 Aug; 47(1):23-31. PubMed ID: 19522736
[TBL] [Abstract][Full Text] [Related]
10. Estrogen regulation of vascular endothelial growth factor in breast cancer in vitro and in vivo: the role of estrogen receptor alpha and c-Myc.
Dadiani M; Seger D; Kreizman T; Badikhi D; Margalit R; Eilam R; Degani H
Endocr Relat Cancer; 2009 Sep; 16(3):819-34. PubMed ID: 19398483
[TBL] [Abstract][Full Text] [Related]
11. c-Myc overexpression and endocrine resistance in breast cancer.
McNeil CM; Sergio CM; Anderson LR; Inman CK; Eggleton SA; Murphy NC; Millar EK; Crea P; Kench JG; Alles MC; Gardiner-Garden M; Ormandy CJ; Butt AJ; Henshall SM; Musgrove EA; Sutherland RL
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):147-55. PubMed ID: 17052904
[TBL] [Abstract][Full Text] [Related]
12. EphA2 overexpression causes tumorigenesis of mammary epithelial cells.
Zelinski DP; Zantek ND; Stewart JC; Irizarry AR; Kinch MS
Cancer Res; 2001 Mar; 61(5):2301-6. PubMed ID: 11280802
[TBL] [Abstract][Full Text] [Related]
13. The docking protein Gab2 is overexpressed and estrogen regulated in human breast cancer.
Daly RJ; Gu H; Parmar J; Malaney S; Lyons RJ; Kairouz R; Head DR; Henshall SM; Neel BG; Sutherland RL
Oncogene; 2002 Aug; 21(33):5175-81. PubMed ID: 12140767
[TBL] [Abstract][Full Text] [Related]
14. Growth factor-dependent regulation of survivin by c-myc in human breast cancer.
Cosgrave N; Hill AD; Young LS
J Mol Endocrinol; 2006 Dec; 37(3):377-90. PubMed ID: 17170079
[TBL] [Abstract][Full Text] [Related]
15. Estrogen regulation of vascular endothelial growth factor gene expression in ZR-75 breast cancer cells through interaction of estrogen receptor alpha and SP proteins.
Stoner M; Wormke M; Saville B; Samudio I; Qin C; Abdelrahim M; Safe S
Oncogene; 2004 Feb; 23(5):1052-63. PubMed ID: 14647449
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation and growth inhibitory role of C/EBPalpha in breast cancer.
Gery S; Tanosaki S; Bose S; Bose N; Vadgama J; Koeffler HP
Clin Cancer Res; 2005 May; 11(9):3184-90. PubMed ID: 15867211
[TBL] [Abstract][Full Text] [Related]
17. High tumoral levels of Kiss1 and G-protein-coupled receptor 54 expression are correlated with poor prognosis of estrogen receptor-positive breast tumors.
Marot D; Bieche I; Aumas C; Esselin S; Bouquet C; Vacher S; Lazennec G; Perricaudet M; Kuttenn F; Lidereau R; de Roux N
Endocr Relat Cancer; 2007 Sep; 14(3):691-702. PubMed ID: 17914099
[TBL] [Abstract][Full Text] [Related]
18. Molecular identification of ERalpha-positive breast cancer cells by the expression profile of an intrinsic set of estrogen regulated genes.
Weisz A; Basile W; Scafoglio C; Altucci L; Bresciani F; Facchiano A; Sismondi P; Cicatiello L; De Bortoli M
J Cell Physiol; 2004 Sep; 200(3):440-50. PubMed ID: 15254972
[TBL] [Abstract][Full Text] [Related]
19. Changes in protein tyrosine phosphatase type IVA member 1 and zinc finger protein 36 C3H type-like 1 expression demonstrate altered estrogen and progestin effect in medroxyprogesterone acetate-resistant and estrogen-independent breast cancer cell models.
Pennanen PT; Sarvilinna NS; Purmonen SR; Ylikomi TJ
Steroids; 2009; 74(4-5):404-9. PubMed ID: 19146866
[TBL] [Abstract][Full Text] [Related]
20. TFAP2C controls hormone response in breast cancer cells through multiple pathways of estrogen signaling.
Woodfield GW; Horan AD; Chen Y; Weigel RJ
Cancer Res; 2007 Sep; 67(18):8439-43. PubMed ID: 17875680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
